Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin + docetaxel for recurrent or metastatic nasopharyngeal carcinoma
ChiCTR-ONC-11001497Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Apr 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lobaplatin and docetaxel in nasopharyngeal carcinoma (NPC), sponsored by Tongji Hospital. Primary endpoints: Objective response rate and Disease control rate. Started Apr 2011; status: completed.
02
Drugs
lobaplatindocetaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-ONC-11001497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-11001497.